Page 123 - MemoriaEHD-Eng

www.ciberehd.org

• s B, g-M C, M M, i M, g e, B p. A
Most relevant aNgrooMezartíNDe La atañarrairaeguiarraLDaarrera
clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular
scientific carcinoma and chronic hepatitis C.J Hepatol. 2013 Jul;59(1):81-8.

articles
• uriarte i, FerNáNDez-BarreNa Mg, MoNte MJ, Latasa Mu, ChaNg hC, Carotti s.
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration

and its application in the prevention of post-resection liver failure in mice.Gut. 2013
Jun;62(6):899-910.

• s M, p-s a, a-a L, D s M, Q C, p J. Nuclear α1-
aNtaMariaarDoagaNtaLvarezsiaiNiCaLaiaNrieto
antichymotrypsin promotes chromatin condensation and inhibits proliferation of human
hepatocellular carcinoma cells.Gastroenterology. 2013 Apr;144(4):818-828.e4.

• g-a B, C a, i M, B Ji, r-F M, r
iLLzugarayhopiteañarrairaeguiiLBaooDríguezraiLeoDríguez
J. Prognostic factors and prevention of radioembolization-induced liver disease.
Hepatology. 2013 Mar;57(3):1078-87.

• g r, B Ji, C L, C r, g D, e s. Comparison of the
oLFieriiLBaoarpaNeseiaNNiaspariNizziDDiN
survival and tolerability of radioembolization in elderly vs. younger patients with

unresectable hepatocellular carcinoma.J Hepatol. 2013 Oct;59(4):753-61.

In immunotherapy of hepatocellular carcinoma we presented the first trial show-
Highlights
ing signs of activity and security of tremelimumab, an anti-CTLA4 monoclonal an-

tibody, paving the way for clinical research on immune checkpoint inhibitors, and
we have identified in preclinical models other strategies such as the use of EDA

(endogenous ligand of TLR4) that targets antigens to dendritic cells; a triple fusion
protein combining Apo AI, IL15, and the sushi domain of IL15Ra that increases the

effectiveness of IL-15; and the combination of three monoclonal antibodies anti-

CD137, anti-OX40 and anti-B7-H1.

In radioembolization we have presented a modified treatment protocol that re-
duces liver complications without altering the efficacy and have confirmed the

good tolerability in elderly patients and the reversibility of gastrointestinal toxicity.

In carcinogenesis and regeneration we have identified two molecules with thera-
peutic potential in hepatocellualr carcinoma: alpha1antichemotrypsin, that con-

trols cell proliferation and its overexpression has antitumor activity in animal

models ; FGF15, a key factor in preventing liver injury during liver regeneration
and makes animal models tolerate subtotal hepatectomies. Furthermore, we have

described that MMP10 is involved in tissue repair and described a new way in

which SULF2 regulates tissue regeneration partly through the activation of a new
pathway Wnt-GLI1-Cyclin D1.

In liver transplantation we have provided new data on patient selection for im-

munosuppression withdrawal, fully laparoscopic living donation, use of everolimus
to improve renal failure, utility of screening for lung cancer and preclinical dem- 13
20
onstration of the utility of cardiotrophin 1 to reduce ischemia- reperfusion injury.
T
OR
We have finally made further progress in the development of gene therapy adeno- P
RE
associated vectors for liver diseases by studying their safety in nonhuman pri- L
mates.
A
NU
N
A
D /
H
E
ER
IB
C

123